Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
A phase 2 trial of Bevacizumab, Sintilimab in hepatocellular carcinoma, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Overview
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT06558227 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 90 participants planned, started 2024-10-24 and due to reach its primary completion in 2026-09. Interventions recorded: ZG005 for Injection, Bevacizumab, Sintilimab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Part
Shares Sintilimab, Hepatocellular carcinoma.
- TrialStudy of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
- TrialORIENT-32
Shares Sintilimab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Sintilimab, Hepatocellular carcinoma.
- TrialA Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Shares Bevacizumab, Hepatocellular carcinoma.